Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Summary

The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.

Timeline

Start

2026-09-01

Primary completion

2028-07-01

Completion

2028-07-01

Drugs

Indications